Since its inception, AMAR has worked to build an extensive patent portfolio for low-dose orally administered interferon. This portfolio consists of patents with claims that encompass method of use or treatment and composition of matter and manufacturing. AMAR believes that its patent protection will ensure its future commercial success within the field of low-dose orally administered interferon use. AMAR presently owns or licenses 5 issued US patents related to interferon. AMAR has vigorously enforced its patent position in the past, resulting in successful settlement. There are no current patent litigation proceedings involving AMAR.